Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Tanum

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
JAMA Psychiatry|December 20, 2018
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up StudyZill-E-Huma Latif, Jurate Šaltyte Benth, Kristin Klemmetsby Solli, et al.
The American Journal on Addictions|September 6, 2021
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical TrialArild Opheim, Zhanna Gaulen, Kristin Klemmetsby Solli, et al.
Journal of Substance Abuse Treatment|December 6, 2021
'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative studyIda Halvorsen Brenna, Anne Marciuch, Bente Birkeland, et al.
JAMA Psychiatry|October 20, 2017
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority TrialLars Tanum, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.
European Addiction Research|July 20, 2016
Interest in Extended Release Naltrexone among Opioid UsersKamni Sharma Haase, Nikolaj Kunøe, Arild Opheim, et al.
Administration and Policy in Mental Health|February 8, 2020
The Antipsychotic Medication Management Fidelity Scale: Psychometric propertiesTorleif Ruud, Karin Drivenes, Robert E Drake, et al.
Addiction (Abingdon, England)|May 29, 2018
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trialKristin Klemmetsby Solli, Zill-E-Huma Latif, Arild Opheim, et al.
BMC Psychiatry|December 11, 2012
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?Jørgen G Bramness, Øystein Hoel Gundersen, Joar Guterstam, et al.
European Addiction Research|July 25, 2019
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical TrialKristin Klemmetsby Solli, Nikolaj Kunoe, Zill-E-Huma Latif, et al.
Journal of Pain Research|November 6, 2019
CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgiaAnne-Li Lind, David Just, Maria Mikus, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
JAMA Psychiatry|December 20, 2018
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up StudyZill-E-Huma Latif, Jurate Šaltyte Benth, Kristin Klemmetsby Solli, et al.
The American Journal on Addictions|September 6, 2021
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical TrialArild Opheim, Zhanna Gaulen, Kristin Klemmetsby Solli, et al.
Journal of Substance Abuse Treatment|December 6, 2021
'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative studyIda Halvorsen Brenna, Anne Marciuch, Bente Birkeland, et al.
JAMA Psychiatry|October 20, 2017
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority TrialLars Tanum, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.
European Addiction Research|July 20, 2016
Interest in Extended Release Naltrexone among Opioid UsersKamni Sharma Haase, Nikolaj Kunøe, Arild Opheim, et al.
Administration and Policy in Mental Health|February 8, 2020
The Antipsychotic Medication Management Fidelity Scale: Psychometric propertiesTorleif Ruud, Karin Drivenes, Robert E Drake, et al.
Addiction (Abingdon, England)|May 29, 2018
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trialKristin Klemmetsby Solli, Zill-E-Huma Latif, Arild Opheim, et al.
BMC Psychiatry|December 11, 2012
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?Jørgen G Bramness, Øystein Hoel Gundersen, Joar Guterstam, et al.
European Addiction Research|July 25, 2019
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical TrialKristin Klemmetsby Solli, Nikolaj Kunoe, Zill-E-Huma Latif, et al.
Journal of Pain Research|November 6, 2019
CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgiaAnne-Li Lind, David Just, Maria Mikus, et al.
Pageof 6